+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      One-Day Renal Function Testing in Normal Rats and in Cases of Experimentally-Induced Analgesic Nephropathy, Nephrocalcinosis and Nephrotic Syndrome

      , ,


      S. Karger AG

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          A number of renal function tests were combined into one 7-hour day in the rat, using urinary tests only to allow sequential measurements in individual animals, and involving 18 measurements for each one-day test. The use of 1.42% sterile sodium sulphate solution containing 3 mg% phenolsulphonphthalein (20 ml/kg) and a mineralocorticoid drug (Florinef, 9-α-fluorohydrocortisone, 0.2 mg/kg) by intraperitoneal injection was found to overcome the difficulty of achieving reproducible values for minimum urinary pH in the rat. Pitressin (antidiuretic hormone) was observed to interfere with minimum urinary pH, and its administration (0.4 units/kg i.p.) was delayed for 2 h. Normal values (mean ± SD) obtained in 64 one-day tests in 40 animals (involving over 1,000 measurements) were as follows: urinary protein (Albustix), 30 ± 15mg%; urinary phenolsulphonphthalein excretion in first hour, 27 ± 5 (males) and 37 ± 7 (females), as percent of injected dose; maximum sodium excretion after sodium load, 1,300 (range 700–2,200) µEq/mg creatinine; minimum sodium excretion after mineralocorticoid load, 10 ± 7 µEq/mg creatinine; maximum sodium excretion/conservation ratio 130 (range 40–1,100); maximum urinary creatinine concentration after Pitressin, 150 ± 35 mg%; and minimum urinary pH in second hour after sulphate load, 5.1 ± 0.2 units. In a 6-week illustrative study of cases of acute experimentally-induced renal disease, the administration of analgesic powders (42% aspirin, 42% phenacetin and 16% caffeine citrate) to 2 cases (8 one-day tests) or acetazoleamide to 3 cases (9 one-day tests) was found to induce defects in urinary concentrating ability after Pitressin and in minimum sodium excretion after a mineralocorticoid load, suggesting specific tubular or vasa recta lesions. Analgesic powders possibly affected the urinary acidification mechanism as well. On the other hand, dosage with puromycin aminonucleoside or human serum albumin in 4 cases (16 one-day tests) produced mainly decreased glomerular function and proteinuria typical of the nephrotic syndrome, with decreased flexibility of urinary sodium excretion.

          Related collections

          Author and article information

          S. Karger AG
          26 November 2008
          : 8
          : 3
          : 235-245
          Keith Kirkland Renal Unit, Medical Research Department, Kanematsu Memorial Institute, Sydney Hospital, Sydney
          179924 Nephron 1971;8:235–245
          © 1971 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11

          Cardiovascular Medicine, Nephrology


          Comment on this article